Search | Science Publications

Research ArticleOpen accessIn the author namesImatinib Mesylate Inhibits Glucose Uptake in Gastrointestinal Stromal Tumor Cells by Downregulation of the Glucose Transporters Recruitment to the Plasma MembraneHans Prenen, Cristiana Stefan, Bart Landuyt et al.Imatinib mesylate, the inhibitor of the KIT protein tyrosine kinase that is constitutively activated in Gastrointestinal Stromal Tumors (GISTs), has been established as the first highly effective drug in the treatment of patients with advanced GISTs. Recent studies suggest that changes in the glucose metabolism could be an additional mechanism of the anti-proliferative action of imatinib. The aim of this … …American Journal of Biochemistry and Biotechnology, Vol. 1, Issue 2 · 30 Jun 2005 · 7,245 accessesView PDF Cite

1 article for “Mathieu Bollen”